IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain Post author:Sam Post published:February 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like How Amicus CEO Personally Appealed to FDA Head to Get Migalastat Back on Track December 14, 2017 Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space July 18, 2017 What You Need to Know About Merck & Co.'s Fearless CEO August 14, 2017